Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.
Haffner D., Emma F., Seefried L., Högler W., Javaid KM., Bockenhauer D., Bacchetta J., Eastwood D., Biosse Duplan M., Schnabel D., Wicart P., Ariceta G., Levtchenko E., Harvengt P., Kirchhoff M., Gardiner O., Di Rocco F., Chaussain C., Brandi ML., Savendahl L., Briot K., Kamenický P., Rejnmark L., Linglart A.
X-linked hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX gene, which is predominantly expressed in osteoblasts, osteocytes and odontoblasts. XLH is characterized by increased synthesis of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23), which results in renal phosphate wasting with consecutive hypophosphataemia, rickets, osteomalacia, disproportionate short stature, oral manifestations, pseudofractures, craniosynostosis, enthesopathies and osteoarthritis. Patients with XLH should be provided with multidisciplinary care organized by a metabolic bone expert. Historically, these patients were treated with frequent doses of oral phosphate supplements and active vitamin D, which was of limited efficiency and associated with adverse effects. However, the management of XLH has evolved in the past few years owing to the availability of burosumab, a fully humanized monoclonal antibody that neutralizes circulating FGF23. Here, we provide updated clinical practice recommendations for the diagnosis and management of XLH to improve outcomes and quality of life in these patients.